Related Experiment Video
Updated: Apr 6, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
QT Interval Length in Elderly Prostatic Cancer Patients on Anti-Testosterone Treatment
The Israel Medical Association Journal : IMAJ
|August 4, 2015
Summary
Anti-testosterone treatment in prostate cancer patients did not significantly prolong the QT interval. This preliminary study found no evidence of increased arrhythmia risk from this treatment, though further research is recommended.
Area of Science:
- Cardiology
- Oncology
- Endocrinology
Background:
- QT segment prolongation is a known risk factor for fatal arrhythmias.
- Previous research suggests a potential link between low testosterone levels and prolonged QT intervals.
Purpose of the Study:
- To compare QT interval length in elderly prostate cancer patients undergoing anti-testosterone treatment versus those not receiving it.
Main Methods:
- Electrocardiograms (ECGs) from 100 prostate cancer patients were analyzed.
- Patients were divided into two groups: 50 on anti-testosterone treatment and 50 not.
- QT interval length was measured using standard methods.
Main Results:
- The mean corrected QT (QTc) interval was 0.45 ± 0.04 sec, near the upper limit of normal.
- No significant difference in QTc interval prolongation was observed between treated and untreated groups after adjusting for confounders.
- Prolonged QTc intervals were similarly prevalent in both groups (48% treated vs. 54% non-treated).
- Furosemide use, but not anti-testosterone treatment, was associated with QT prolongation.
Conclusions:
- This preliminary study does not support concerns of significantly prolonged QT intervals in patients receiving anti-testosterone treatment.
- Further prospective studies are necessary to confirm these findings.
- Close monitoring of QT interval length is advised for patients on anti-testosterone therapy.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
357
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
357
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
94
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
94
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
325
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
325